Why Partner?

Following an initial explosion of excitement across the allogeneic space, challenges around safety and long term persistence and durability has highlighted the need for the industry to determine key contributing factors affecting the product performance – one of which is the starting quality of the cell source material being utilized.

And as the allogeneic space continue to ramp up clinical development, drug developers are realizing the need to plan ahead in donor management and develop robust processes to support scale up.

Whilst the allogeneic approach holds powerful potential to transform the entire cell therapy space, the leading industry experts in the field have mentioned they require meaningful partnerships to achieve their clinical and commercial objectives.

The Donor Selection and Cell Source Summit will provide the unique opportunity to position your trusted expertise to those at the forefront of building out their donor requirements for allogeneic cell therapy pipelines. Ensure you capitalize on market share early and show your support in the growth of these therapies.